Largo Announces Results of its Annual General Meeting of Shareholders

TORONTO--(BUSINESS WIRE)-- Largo Inc. ("Largo" or the "Company") (TSX: LGO) (NASDAQ: LGO) announces voting results from its Annual General Meeting of Shareholders (the “Meeting”) held on Monday, July 29, 2024.

A total of 47,142,917 common shares of the Company were voted at the Meeting, representing 73.53% of the Company’s issued and outstanding common shares. Shareholders voted to approve all matters brought before the Meeting, including the election of all director nominees and the appointment of KPMG LLP as the Company’s auditors for the ensuing year.

Largo's Board of Directors wishes to thank its shareholders for their continued support. Detailed results of the votes on the election of directors are as follows:

For further detailed voting results on the Meeting, please refer to the Company’s Report of Voting Results filed on SEDAR+ at www.sedarplus.ca and on www.sec.gov.

About Largo

Largo is a globally recognized vanadium company known for its high-quality VPURETM and VPURE+TM products, sourced from its Maracás Menchen Mine in Brazil. The Company is currently focused on ramping up production of its ilmenite concentrate plant and is undertaking a strategic evaluation of its U.S.-based clean energy business, including its advanced VCHARGE vanadium battery technology to maximize the value of the organization. Largo's strategic business plan centers on maintaining its position as a leading vanadium supplier with a growth strategy to support a low-carbon future.

Largo’s common shares trade on the Nasdaq Stock Market and on the Toronto Stock Exchange under the symbol "LGO". For more information on the Company, please visit www.largoinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729507318/en/

Investor Relations
Alex Guthrie
Senior Manager, External Relations
+1.416.861.9778
[email protected]

Source: Largo Inc.

You May Also Be Interested In

• Leader's Advantage Acquisition Corp. closes $150M IPO on Nasdaq
• Arbe Robotics prices $15M direct offering at $0.60 per share
• FDA approves Merck and Eisai kidney cancer combination therapy